Results for
"[search-keyword]"
Sponsor content
252 result(s) found, displaying 31 to 40
-
-
Australian Public Assessment Report (AusPAR)AusPAR for Rybrevant (amivantamab) for treatment of patients with NSCLC that has an EGFR exon 20 insertion mutation.
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial.
-
Prescription medicine decision summaryThe medicine Tecvayli (teclistamab) has been approved by the TGA to treat multiple myeloma.
-
Prescription medicine registrationActive ingredients: T cells - Ciltacabtagene autoleucel, cryopreserved - T - CARVYKTI .
-
Prescription medicine registrationActive ingredients: teclistamab.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PONVORY ponesimod 20 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PONVORY ponesimod 2 mg + 3 mg + 4 mg + 5 mg + 6 mg + 7 mg + 8 mg + 9 mg + 10 mg film-coated tablets (Treatment initiation pack) blister composite pack.